Rhythm Pharmaceuticals is a global commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway diseases by rapidly advancing care and precision medicines addressing the root cause. To learn more, please visit https://www.rhythmmedicalgateway.com/index.html.
Rhythm has commercialized IMCIVREE (setmelanotide), a precision medicine designed to re-establish MC4R pathway signaling, targeting a root cause of hyperphagia and severe obesity caused by certain rare MC4R pathway diseases. IMCIVREE is the first-ever FDA-approved therapy for patients 6 years and older with obesity due to pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiencies, or Bardet-Biedl syndrome (BBS). For more information about IMCIVREE, including prescribing and safety information, visit https://www.IMCIVREE.com.
Rhythm continues to advance its clinical research program in MC4R pathway diseases, with multiple ongoing and planned Phase 2 and Phase 3 clinical trials for the use of setmelanotide in several distinct, genetically defined MC4R pathway diseases, as well as for use in patients with hypothalamic obesity. For more details on our comprehensive clinical development program, please visit https://www.rhythmtx.com/overview/.
In addition to clinical trials, Rhythm continues to be a leader in understanding rare MC4R pathway diseases. Rhythm has developed the Uncovering Rare Obesity Program, which provides no-cost, comprehensive genetic testing to support diagnosis of rare MC4R pathway diseases. Rhythm is building the largest database of DNA sequences from individuals living with severe obesity to improve the understanding of MC4R pathway diseases. For more information, visit https://UncoveringRareObesity.com.
Rhythm Pharmaceuticals, Inc.
222 Berkeley Street, 12th Floor
Boston, MA 02116
Have questions? Please contact:
Enter the MAP Spotlight Raffle